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This report offers a consensus opinion on the diagnosis, epidemiology, treatment, and prevention of leptospirosis in dogs, an
important zoonosis. Clinical signs of leptospirosis in dogs relate to development of renal disease, hepatic disease, uveitis, and
pulmonary hemorrhage. Disease may follow periods of high rainfall, and can occur in dogs roaming in proximity to water
sources, farm animals, or wildlife, or dogs residing in suburban environments. Diagnosis is based on acute and convalescent
phase antibody titers by the microscopic agglutination test (MAT), with or without use of polymerase chain reaction assays.
There is considerable interlaboratory variation in MAT results, and the MAT does not accurately predict the infecting
serogroup. The recommended treatment for optimal clearance of the organism from renal tubules is doxycycline, 5 mg/kg PO
q12h, for 14 days. Annual vaccination can prevent leptospirosis caused by serovars included in the vaccine and is recommended
for dogs at risk of infection.
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L
eptospirosis is a zoonotic bacterial disease with a
worldwide distribution, and is an emerging infec-
tious disease in humans
1 and in dogs.
2,3 It has been
reported in over 150 mammalian species.
4 Leptospira
spp. are thin, motile spirochetes with a hook-shaped
end. Both saprophytic and pathogenic species exist in
nature. Saprophytic species, such as Leptospira biﬂexa,
live in water and soil and do not infect animals. Lepto-
spires phylogenetically and pathogenically intermediate
to these 2 groups also have been identiﬁed in humans and
animals, but not yet in dogs.
5,6 There are over 250 patho- genic serovars based on differences in the carbohydrate
component of the bacterial lipopolysaccharide.
1,4 Differ-
ent serovars are adapted to different wild or domestic
animal reservoir hosts, and thus serovar recognition has
epidemiologic importance. Serovars are further grouped
into antigenically related serogroups (Table 1). Immu-
nity to leptospires is serogroup speciﬁc, and knowledge
of serogroups that commonly cause disease within a
particular geographic region is important for vaccine
development.
Disease in dogs is caused primarily by Leptospira
interrogans and Leptospira kirschneri. Leptospira wolﬁi
was identiﬁed in dogs in Iran, but its role as a canine
pathogen requires further study.
7 Leptospira noguchii
was isolated from a sick dog in Brazil.
8 The most
common serovars thought to infect dogs before the
introduction of leptospirosis vaccines 30 years ago were
Icterohaemorrhagiae and Canicola. Since the introduc-
tion of bivalent Icterohaemorrhagiae and Canicola
vaccines, more widespread involvement of additional
serovars has been suspected, including Grippotyphosa,
Pomona, Bratislava, and Autumnalis.
9–14 Increased
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J Vet Intern Med 2011;25:1–13recognition of leptospirosis associated with these sero-
vars may have resulted partly from increased testing,
because a broader range of serovars has been included in
microscopic agglutination test (MAT) serology for ca-
nine leptospirosis. It also may have resulted from
increased contact between dogs and the reservoir hosts
for these serovars.
2 The pathogenic relevance of the
serovar classiﬁcation has been problematic, because
both pathogenic and nonpathogenic leptospires can be-
long to the same serovar, presumably as a result of
transfer of genes determining serotype among different
species.
4,15
The need for a Consensus Statement was suggested at
the 2008 ACVIM Forum Infectious Disease Study
Group (IDSG) meeting for several reasons: increasing
recognition of canine leptospirosis associated with
development of antibodies to previously unrecognized
serovars, studies suggesting poor prediction of the infect-
ing serovar by the MAT and interlaboratory variation
in test results, concerns regarding the risk of zoonotic
transmission, and questions regarding vaccine safety
and efﬁcacy. During the 2009 ACVIM Forum, the IDSG
sponsored an interactive session led by Drs Sykes,
Goldstein, Lunn, Moore, and Hartmann. The ACVIM
Board of Regents then selected the topic for a Consensus
Statement, and identiﬁed a chairperson (Sykes) and panel
members. The panelists used the available literature to
present evidence-based justiﬁcation for recommendations
on which there appeared to be a consensus. A draft was
presented verbally at the 2010 ACVIM Forum, and a writ-
ten draft was posted on the ACVIM web site for comments
by the membership before submission of a revised manu-
script to the ACVIM Board of Regents and the editors of
the Journal of Veterinary Internal Medicine.
What Clinical Syndromes Are Associated with
Canine Leptospira Infection?
Infection of dogs with leptospires results in illness
of varying severity, depending on the infecting strain,
geographical location, and host immune response. Some
dogs display mild or no signs of disease, whereas others
develop severe illness or death, often as a result of
renal injury. In general, veterinarians should suspect le-
ptospirosis in dogs with signs of renal or hepatic failure,
uveitis, pulmonary hemorrhage, acute febrile illness, or
abortion.
Fever occurs early in the course of illness, and may be
accompanied by shivering, generalized muscle tenderness,
and reluctance to move. Dogs presenting with acute renal
failure may show polyuria, polydipsia, dehydration,
vomiting, diarrhea, inappetence, lethargy, or abdominal
pain or some combination of these signs.
13,16–20 Oliguria or
anuria also may occur. Dogs may present with signs
of hepatic failure, including icterus.
19,20 Other reported
manifestations of infection include conjunctivitis,
18,21
uveitis,
22,a and tachypnea or dyspnea because of acute
respiratory distress syndrome or leptospiral pulmonary
hemorrhage syndrome (LPHS), which has been reported
most frequently in dogs from some parts of Europe.
19,20,23,b
LPHS isincreasingly recognized inhumanpatients, appears
to have an immune-mediated basis, and is associated with
high mortality.
4,24,25 Pathologic lesions in dogs resemble
those described in humans.
20 Changes suggestive of
pancreatitis have been detected in some dogs by abdominal
ultrasonography. Hematuria can occur after natural and
experimental infection.
19,20 Bleeding tendencies also may be
manifested as hematemesis, hematochezia, hemoptysis, me-
lena, epistaxis, and petechial hemorrhages.
19,20,21,26 The
pathophysiologic mechanisms of bleeding in dogs and
humans with leptospirosis are incompletely understood.
27
Hepatic failure, disseminated intravascular coagulation
(DIC), and direct vascular damage by spirochetes may play
variable roles. Vasculitis also may be manifested as periph-
eral edema and mild pleural or peritoneal effusion.
Meningitis is recognized in people with leptospirosis, but
has not been documented in dogs. Cardiac damage occurs
in human patients
28 and ECG alterations suggesting myo-
cardial damage can occur in dogs.
26 Abortion has occurred
in dogs after transplacental spread of serovar Buenos
Aires,
29 and 1 report suggested abortion associated with
serovar Bratislava infection.
30
Polyuriaandpolydipsiacandevelopindogswithlepto-
spirosis in the absence of azotemia. In some cases, this
may result from a decreased glomerular ﬁltration rate
sufﬁcient to cause impaired renal concentrating ability.
However, these patients also may be hyposthenuric.
19,31
Experimentally, leptospiral infection causes decreased
vasopressin responsiveness of the inner medullary
collecting ducts,
32 suggesting polyuria may result from
acquired nephrogenic diabetes insipidus.
Table1. Leptospiral serogroups and serovars isolated from dogs suspected to have leptospirosis, or that induce
disease after experimental inoculation of dogs.
Species Serogroup Serovar Country References
Leptospira interrogans Icterohaemorrhagiae Icterohaemorrhagiae USA, France 21,70–72,74–79
Canicola Canicola India, USA 21,65,66,74–79
Pomona Pomona USA 17
Australis Bratislava USA 81
Sejroe ND Germany 82
Autumnalis Autumnalis India, France 62,80
Djasiman Buenos Aires Argentina 29
Ballum Ballum USA 49
Leptospira kirschneri Grippotyphosa Grippotyphosa USA 18,48
Leptospira noguchii Australis ND Brazil 8
2 Sykes et alChronic active hepatitis was reported in 1 kennel in
association with development of antibodies to serovar
Grippotyphosa
33 and in another to serovar Australis.
34
Attempts to detect leptospiral DNA in liver samples
from dogs with chronic hepatitis were unrewarding.
35
Leptospirosis should be considered as a differential diag-
nosis in dogs with hepatitis or hepatic ﬁbrosis. Similarly,
dogs surviving acute renal tubulointerstitial injury may
have residual chronic kidney injury that progresses over
months to years, culminating in signs of decompensated
chronic kidney disease.
Attempts have been made to correlate the infecting
serovar with clinical presentation.
13,14 Evidence for a
correlation has been weak because of the poor ability of
antibody tests to predict the infecting serovar, and lateral
transfer of virulence attributes may occur between
serovars.
4,15 Thus at this time, no clear correlation has
been made between the suspected infecting serovar based
on antibody testing and clinical manifestations of disease
in naturally occurring canine leptospirosis. No associa-
tions between clinical manifestations and infecting
serovars have been detected in human patients,
1 and
multiple serovars have been isolated from humans in
some outbreaks.
36 Future attempts to correlate clinical
presentation and infecting leptospiral strain should be
based on a combination of isolation, serotyping, and
genetic studies.
Does Leptospirosis Occur in Cats?
Although serologic evidence of exposure of cats to
leptospires exists,
37–39 clinical disease in cats is rarely
reported.
40–42 Serovars Canicola, Grippotyphosa, and
Pomona have been isolated from cats. Experimental in-
fection of cats results in leptospiremia and leptospiruria,
but disease is generally mild,
43–45 although histopathologic
evidence of renal and hepatic inﬂammation can be present.
Cats may be exposed as a result of rodent contact.
37 The
extent to which cats contaminate the environment with
leptospires is unknown.
What Is the Geographic Distribution of
Leptospirosis in Dogs?
Leptospirosis is especially prevalent in geographic re-
gions with higher annual rainfall and warm climates, but
factors such as host exposure and the presence of wild
and domestic animal reservoir hosts also inﬂuence geo-
graphic distribution of the disease. For humans, the
Caribbean and Latin America, the Indian subcontinent,
Southeast Asia, Oceania, and to a lesser extent Eastern
Europe are major disease foci. Hawaii accounts for most
human cases in North America.
46 Within the United
States, regions of high antibody prevalence (titers
1,600) among dogs include Hawaii, the west coast (es-
pecially northern California, Oregon, and Washington),
the upper Midwest and Midwest parts of Texas, Colo-
rado, and the northeast and mid-Atlantic coastal regions
(unpublished observations).
47 Canine leptospirosis also
occurs in the southeastern United States.
48,49
What Risk Factors Predispose Dogs to
Leptospirosis?
Pathogenic leptospires infect and are shed from the renal
tubules of a wide range of domestic and wild animals.
Naı¨ve animals become infected by contact of intact mu-
cous membranes or abraded skin with infected urine or
urine-contaminated soil, water, food, or bedding.
1,4 Lepto-
spires do not replicate outside of the host but may remain
viable for weeks to months in soil saturated with urine.
50
Transmission also has occurred after bite wound inocula-
tion, ingestion of infected tissues, and venereal and
placental transfer. In 1 study from Thailand, ingestion of
raw meat by dogs was associated with leptospirosis.
51
The organism prefers temperatures around 301C, and
freezing and UV radiation inactivate leptospires. Con-
tact with slow-moving or stagnant warm water is a risk
factor in humans.
52–55 Outbreaks of disease in dogs have
followed periods of higher rainfall,
16,56 with overall peak
seasonal distribution occurring in the late fall in the
United States.
57 The time of year for peak leptospirosis
incidence varies geographically depending on local rain-
fall patterns and periods of freezing temperatures.
a In
some geographic regions, disease generally occurs in
dogs that are exposed to or drink from rivers, lakes, or
streams,
58,59 or dogs roaming on rural properties. In
others, suburban backyard dogs may be exposed after
contact with urbanized wild animal populations. In de-
veloping countries, access to sewage increases risk of the
disease in dogs.
51 Outdoor, intact male working dogs
have been shown to be at risk,
60 although dogs of any
age, breed, and sex may become infected. In areas where
wild animal species access suburban backyards, small
breed dogs with minimal contact with water sources may
be at risk. Contact with rodents also may pose a risk to
these dogs, as well as dogs residing within cities.
61
What Is the Incubation Period for Leptospirosis
in Dogs?
The incubation period for leptospirosis can be as short
as a few days, the organisms replicating rapidly within
the blood as early as 1 day after infection before invading
tissues.
62 The incubation period in experimental studies
has been 7 days, but varies depending on the infecting
dose, strain, and host immune response.
17 Shorter incu-
bation periods can occur with large inocula, and longer
incubation periods may occur after low-grade, chronic
infections of the renal tubules or hepatocytes,
63,64 with
clinical illness not being detected until some time after
renal or hepatic injury.
What Serovars Cause Disease in Dogs?
Infecting serovars vary geographically among dog
populations depending on exposure to infected wild or
domestic animal reservoir hosts. A complete understand-
ing of infecting serovars in the dog population has
been limited because published studies usually have
not included isolation efforts. Furthermore, the MAT
has poor ability to predict the infecting serogroup.
3 LeptospirosisAlthough dogs are considered maintenance hosts
for leptospires in serogroup Canicola, the prevalence of
seroreactivity to this serogroup in dogs from the United
States and Europe currently is low. Infection with
serogroup Canicola serovars was reported in dogs from
the United States in the 1950s and 1960s.
65,66 Chronic
canine infection with leptospires may be an ongoing pub-
lic health problem in developing countries.
67–69 Serovar
Icterohaemorrhagiae, the major serovar infecting
humans worldwide,
4 is often found in rodent popula-
tions and was isolated from dogs in the United States
before 1980.
70–72 Based on antibody testing, evidence of
canine infection by this serovar is less common now, pos-
sibly because of improved rodent control and other
public health measures in cities and on farms in the
United States. A high prevalence of seroreactivity to
serogroup Icterohaemorrhagiae sometimes has been
documented in nonrodent periurban wildlife (eg,
raccoons
73), and the role of transmission of serovar
Icterohaemorrhagiae by these hosts is unclear. Given
that the MAT is not effective for predicting the infecting
serovar, more studies by isolation are required to conﬁrm
the importance of various wildlife hosts as reservoirs of
serogroup Icterohaemorrhagiae.
Serovars from serogroups Icterohaemorrhagiae
and Canicola cause disease in dogs after experimental
inoculation.
21,74–79 A study from India reported disease in
dogs experimentally infected with serovars Autumnalis
and Canicola.
62 An Autumnalis serovar was isolated
from sick dogs in France.
80 A Pomona serovar caused
disease after experimental inoculation of dogs.
17 In the
same study, inoculation of dogs with a serovar Bratislava
isolate did not result in disease or seroconversion. How-
ever, another Bratislava serovar was isolated from a dog
withleptospirosis.
81 Antibody titers toserovar Bratislava
(serogroup Australis) often increase with titers to Grip-
potyphosa and Pomona, and thus in some cases serologic
evidence of serovar Bratislava exposure may represent
cross-reactivity. Serovar Grippotyphosa also causes dis-
ease in dogs,
18,48 and other studies have reported disease
in association with serogroups Sejroe
82 and Ballum.
49
Although an Autumnalis serovar was isolated from
raccoons in Georgia in the 1950s, the panel is unaware
of any serovar Autumnalis isolates from dogs in North
America. Antibody titers to serovar Autumnalis often
increase together with antibody titers to serovars Grip-
potyphosa, Pomona, and Bratislava. Nonspeciﬁc increases
in titers to serogroup Autumnalis have been observed in
dogs with diseases other than leptospirosis, and in dogs
vaccinated for or infected with serogroup Pomona or
Grippotyphosa (unpublished observations), and caution
is advised when interpreting titers to this serovar.
What Clinicopathologic Abnormalities
Are Expected in Dogs with Leptospirosis?
Renal tubular infection by leptospires is associated
with acute interstitial nephritis and tubular dysfunction,
although acute tubular necrosis can occur in naturally
infected dogs.
20 Mesangial proliferative glomerulone-
phritis and interstitial nephritis were associated with
seropositivity in 1 study, but the dogs evaluated were
strays and confounding factors, such as coinfections may
have existed.
9 Histopathologic changes in the liver often
are mild and can include mild to moderatescattered hepatic
necrosis
20 and mild neutrophilic periportal hepatitis.
Findings on CBC may include neutrophilia, sometimes
with a left shift, lymphopenia, and mild to moderate, non-
regenerative anemia. Uncommonly, severe anemia occurs,
21
which may follow gastrointestinal or pulmonary hemor-
rhage. In contrast to what is observed in cattle, hemolysis
does not appear to be a feature of canine leptospirosis.
Thrombocytopenia is present in up to 58% of affected
dogs,
13,14,19,20,26 and when accompanied by evidence of
acute kidney damage with or without hepatic injury, can
help increase suspicion for a diagnosis of leptospirosis.
Increased serum urea and creatinine concentrations
may be present in 480–90% of dogs,
13,19,20,26,a although
in 1 European study, increased serum creatinine con-
centration was present in only 57% of affected dogs.
14
Hepatic dysfunction may be manifested by increases in
serum ALT, AST, and ALP activities and total bilirubin
concentration, almost always in conjunction with
azotemia.
13,14,19,20,26,a Increases in serum ALP activity
and total bilirubin concentration are more common than
increases in the activity of serum ALT.
2,13,19,20,31,48,83 A
combination of azotemia and increased liver enzyme
activitiesshould markedly increasesuspicion forleptospiro-
sis. Electrolyte abnormalities may be a consequence of
gastrointestinal or renal ﬂuid losses. Inhibition of Na
1-K
1
ATPase activity within the nephron by leptospiral endo-
toxin may contribute to renal losses.
84 Hyponatremia, hypo-
chloridemia, marked hypokalemia, and hyperphosphatemia
occur in many cases, but dogs with oliguric or anuric renal
failure may become hyperkalemic. Leptospires are known to
induce hypokalemic, nonoliguric renal failure in humans as a
consequence of impaired tubular sodium reabsorption,
85
and the same may occur in dogs.
Increased serum creatine kinase activity also may be
present, presumably because of myositis.
26 Increased se-
rum troponin concentrations in some dogs suggest
myocardial damage.
26
Urinalysis from dogs with leptospirosis may show iso-
sthenuria, occasionally hyposthenuria. Glucosuria and
proteinuria are common in some geographic locations,
20
and bilirubinuria, hematuria, pyuria, and cylindruria
also may be present.
13,20,26 Although high-molecular
weight proteins have been detected in urine from some
dogs with leptospirosis,
26 results of another study sug-
gested proteins were primarily tubular, rather than
glomerular, in origin.
86 Leptospires are not visible in the
urine sediment by routine light microscopic evaluation.
Clotting function assays in dogs with leptospirosis
show variable increases in ﬁbrinogen, D-Dimer and ﬁ-
brinogen degradation product concentrations, and
decreases in antithrombin activity, in addition to throm-
bocytopenia.
26,87 Prolongations of PT or PTT have been
detected 6–50% of tested dogs.
13,20,26 Prolongationswere
most prevalent in western European dogs.
20 A shortened
PT also may be present, possibly because of DIC.
Thoracic radiographs from dogs with leptospirosis
may show diffuse interstitial patterns or more severe
4 Sykes et alnodular interstitial to alveolar patterns.
20,23,b Abdominal
sonography can disclose nonspeciﬁc ﬁndings including
renomegaly, increased cortical echogenicity, perirenal
ﬂuid accumulation, mild pyelectasia, and a medullary
band of increased echogenicity.
88 Enlargement and hy-
poechogenicity of the pancreas, thickening of the gastric
and (less commonly) intestinal wall, splenomegaly with a
mottled splenic echotexture, and mild abdominal lymph-
adenomegaly also may be found.
How Should Antibody Testing Be Used to
Diagnose Canine Leptospirosis?
Use of antibody testing for diagnosis of leptospirosis
generally is based on the MAT, which involves reacting
serial dilutions of patient sera with an array of live
leptospiral serovars, and assessment of organism agglu-
tination by darkﬁeld microscopy. The highest serum
dilution causing agglutination of 50% of the leptospires
in the reaction is reported to the veterinarian. The MAT
is widely available and inexpensive, and there is a large
body of data regarding its use; as such, it is the current
diagnostic test of choice for canine leptospirosis in pa-
tients with consistent clinical signs. Unfortunately, the
test is hazardous to perform because of the need to main-
tain live cultures of pathogenic serovars, and is difﬁcult
to standardize. Test interpretation is somewhat subjec-
tive and requires considerable expertise, and serovar
identity must be veriﬁed regularly to ensure accurate
results.
89,90 Serovar cultures may become cross-contam-
inated over time. Considerable variation in results has
been noted among laboratories performing the MAT
for diagnosis of canine leptospirosis, possibly as a result
of variable quality control and standardization.
c There
is a lack of consensus over what titer should be used as
a cut-off for a negative result. The International
Leptospirosis Society offers an inexpensive leptospirosis
testing proﬁciency scheme that enables laboratories to
maintain quality assurance for the MAT on a regular
basis.
89,91 Laboratory participation in the scheme is en-
couraged and it is recommended that practitioners use
laboratories that participate in this program. Molecular
methods also have been advocated to ensure quality con-
trol within leptospiral reference laboratories.
92
In the 1st week of illness, dogs frequently have
negative MAT results, and consequently acute and con-
valescent phase antibody testing is recommended.
Traditionally, convalescent titers for acute infectious
disease diagnosis are performed 2–4 weeks after the acute
titer, although seroconversion can occur as early as 3–5
days after dogs are brought to a veterinarian. Practition-
ers should wait 7–14 days between successive titers to
demonstrate seroconversion. A 4-fold change in titer
supports recent infection, although an increase in titer
may be blunted by antimicrobial therapy. Titers resulting
from previous vaccination, exposure, or chronic infec-
tion generally change more slowly or not at all. Titers can
persist for at least 1 year after natural infection, and in
1 study, generally declined by 4 months after vaccina-
tion.
93 Postvaccinal titers may persist for longer and be
maintained at high levels if ongoing exposure to ﬁeld
strains occurs. Thus, although single positive titers can
increase suspicion for the disease, even when high
(800), they do not conﬁrm a diagnosis of leptospirosis.
This is especially important in dogs with a history of
vaccination, because although postvaccinal titers tend to
be low, high titers (1,600) have the potential to persist
after vaccination, and cross-reactivity to nonvaccinal
serogroups can occur.
93 In 1 study, the sensitivity of
a single MAT titer 800 for diagnosis was 22–67%,
depending on the laboratory used, and the speciﬁcity
was 69–100%.
d
False negative titers may occur if the infecting serovar
is not including in the panel of serovars used to perform
the test. MAT tests used for diagnosis of human
leptospirosis generally include a larger panel of serovars
(420) than those used for veterinary diagnostic testing
(5–7 serovars). MAT assays for canine leptospirosis
should include serovars known to be circulating in the
local dog population, although this information is not
always readily available.
What Are the Limitations of Antibody Testing
for Understanding the Epidemiology of Canine
Leptospirosis?
The MAT is a serogroup- rather than a serovar-
speciﬁc test, because antibodies to serovars within the
same serogroup cross-react extensively.
1 Because of
shared antigens, some cross-reactivity among different
serogroups also occurs after human and canine exposure
to leptospires. In the past, the serogroup with the highest
titer has been interpreted as the infecting serogroup.
However, studies of infected humans with culture-proven
infections have shown that accurate prediction of the in-
fecting serovar occurs in o50% of cases.
94 Higher, cross-
reactive titers can occur to a noninfecting serovar. These
so-called ‘‘paradoxical reactions’’ are especially common
in early infection, and when multiple serovars circulate
within the population.
1,69 Furthermore, the MAT used to
perform studies in humans included approximately 20
serovars, and the serovars included in the test reﬂected
thosecirculating inthepopulation.
94 Evenlower speciﬁcity
could be predicted when the number of serovars included
in the test is small and not reﬂective of actual serovars
infecting the dog population in a speciﬁc geographic
region.
The predicted identity of the infecting serogroup also
has been shown to change over the course of infection in
dogs.
c Previous vaccination can inﬂuence the pattern of
serovarreactivity.
93Indogs,the serogroupwiththe highest
titer also varies depending on which laboratory performs
the MAT, again likely reﬂecting the lack of standardiza-
tion of the assay.
c Thus, the results of the MAT are not
recommended to predict serogroups circulating in the dog
population. Instead, studies involving isolation of lepto-
spires from dogs are recommended for epidemiological
p u r p o s e s ,a sw e l la sf o rs e l e c t i o no fa n t i g e n sf o rd i a g n o s t i c
assay development and vaccine design.
5 LeptospirosisHow Should Polymerase Chain Reaction
(PCR) and Culture Be Used to Diagnose
Canine Leptospirosis?
Culture and PCR detect pathogenic leptospires or
their nucleic acid, respectively, and have potential utility
early in the course of untreated infection when antibody
assays are frequently negative and antimicrobials have
not yet been administered. They also can conﬁrm active
infection in animals with positive antibody test results
that have a history of vaccination with leptospiral vac-
cines, because previous vaccination should not yield false
positive results by these methods.
e They may detect in-
fection in dogs with chronic renal or hepatic disease.
In the ﬁrst 10 days of infection, organism numbers are
highest in blood, and thus blood is the sample of choice
during the ﬁrst week of illness.
17 After that time, organ-
isms are present in highest concentration in urine. When
the time of infection is unknown, simultaneous testing of
blood and urine may increase diagnostic sensitivity. Re-
cent antimicrobial treatment can result in false negative
test results for both culture and PCR, although multiple
doses of antimicrobials may be required before PCR
becomes negative, because PCR detects both viable and
nonviable organisms.
Culture of leptospires requires special media.
f Organ-
isms may be destroyed during transport to the
laboratory. The growth of leptospires is slow, requiring
incubation for up to 3–6 months, and consequently cul-
ture is not useful for early diagnosis. Overgrowth with
other bacteria may occur in contaminated cultures. For
optimal sensitivity, venous blood should be collected by
aseptic technique and immediately inoculated (alongside
the patient) into blood culture bottles containing culture
medium for Leptospira before sending the inoculated
bottles to the laboratory.
95 After the 1st week of illness,
urine should be collected by cystocentesis, and 1 drop of
urine should be inoculated into 5mL of culture medium
within 2 hours of collection. Cultures must be performed
by laboratories with expertise in isolation and identiﬁca-
tion of leptospires, and the commercial availability of
leptospiral culture is not widespread. However, a proper
understanding of the epidemiology of leptospirosis de-
pends upon serotyping and genetic typing after isolation,
and thus attempts to isolate leptospires from dogs with
leptospirosis are encouraged.
PCR assays for detection of leptospiral nucleic acid are
increasingly offered by commercial veterinary diagnostic
laboratories worldwide. Both conventional and real-time
assays have been developed, and their use has been
reported.
20,96–99 Although PCR assays have been designed
to detect only pathogenic leptospiral serovars, currently
available assays do not differentiate between serovars or
serogroups and thus are not useful for studying the
epidemiology of leptospiral strains. Recent reports suggest
that PCR typing methods may be used to some extent to
identify infecting serovars.
100 Not all PCR assays are alike
and they vary considerably in their performance. Negative
results do not rule out leptospirosis, because they may
occur when organism numbers in a sample are low,
or other factors, such as PCR inhibitors, are present.
Currently, there is limited information regarding the valid-
ity of PCR assays for detection of pathogenic leptospires
infecting dogs, as well as their sensitivity, speciﬁcity, and
positive predictive value, and so positive and negative
test results should always be interpreted in conjunction
with other diagnostic methods such as acute and convales-
cent phase antibody testing. The sensitivity of 1 assay
on blood was greatest when whole blood, as opposed to
sera, was used. Sensitivity was 90% in the ﬁrst 5 days of
illness, after which it decreased to 50% (Riediger et al,
manuscript in preparation). Because apparently healthy
dogs may shed leptospires, a positive PCR test result on
urine may not necessarily correlate with illness but is useful
to identify a chronic carrier state.
99,101
Other methods that can be used to conﬁrm the presence
of Leptospira spp. in tissues include silver staining of biopsy
or necropsy specimens (which lacks sensitivity), immuno-
histochemistry, tissue PCR, and in situ hybridization.
102
Are Other Diagnostic Assays for Canine
Leptospirosis Needed?
Given the insensitivity of the MAT in the 1st week of
illness, the hazardous and subjective nature of the MAT,
the potentially fatal consequences of inadequate therapy,
and the zoonotic risks relating to handling dogs with
leptospirosis, assays having high sensitivity early in the
course of illness and a rapid turn-around time have clear
beneﬁt. Although nucleic acid-based assays have the po-
tential to fulﬁll this need, low-cost rapid assays for IgM
or leptospiral antigen that could be performed as point-
of-care tests would be useful. An IgM immunoblot assay
was 88% sensitive in the ﬁrst 3 days of human leptospiro-
sis compared with 2% for the MAT.
103 Use of rapid,
broadly reactive antibody assays as screening tests before
performing the more speciﬁc and cumbersome MAT
may help decrease false negative test results relating to
inadequate serovar inclusion in the MAT and negate the
need for subsequent MAT testing in dogs that test nega-
tive by screening assays. New antibody assays should be
validated in the geographic region in which they are to be
used, because sensitivity may be affected by regional
differences in serovar prevalence. Ideally, they should
detect antibodies that react only with pathogenic ser-
ovars. Recombinant LipL32-based assays recently were
evaluated and found to be sensitive and speciﬁc in dogs
and humans compared with MAT testing.
104,105
Rapid and sensitive assays for organism detection that al-
low subsequent organism typingb ym o l e c u l a rm e t h o d sa l s o
are needed for epidemiologic studies and vaccine design.
Ideally, these assays should allow prediction of the serovar
present, reservoir preferences, and virulence attributes.
What Antibiotics ShouldBe Used forTreatment of
Canine Leptospirosis?
The role of antimicrobial therapy in the treatment of
human leptospirosis has been controversial.
106,107 Treat-
ment initiated after 4–7 days of illness is less effective
in promoting clinical recovery. Nevertheless, the World
Health Organization recommends that all human patients
6 Sykes et aldiagnosed with leptospirosis be treated with antimicrobial
drugs.
95 Treatment for 7 days has been used.
108–110
The optimal treatment for leptospirosis is unknown.
Penicillinsordoxycyclinetraditionally havebeentheanti-
microbials of choice for treatment of humans and dogs
with leptospirosis.
107,108 Ceftriaxone and cefotaxime are
as efﬁcacious as penicillin in human leptospirosis.
107,109
Azithromycin also may be effective.
110 First generation
cephalosporins appear less effective, and leptospires are
resistant to chloramphenicol.
111 The use of ﬂuoro-
quinolones has been controversial. Efﬁcacy similar to
doxycycline in hamsters has required doses 25mg/kg/
d.
112 In 1 study that used quantitative PCR for leptospi-
ral detection, oﬂoxacin was unable to clear leptospires
from the kidneys and blood of a hamster model, amp-
icillin did not clear organisms from the kidney, but
doxycycline cleared organisms from all sites within 3
days of infection.
113 Orbiﬂoxacin was ineffective in 1 dog
with leptospirosis that responded to amoxicillin.
114
Based on these data, the consensus panel recommends
treatment of canine leptospirosis with doxycycline, 5mg/
kg PO or IV q12h for 2 weeks, but the optimal duration of
antimicrobial therapy requires further investigation.
Treatment should not be delayed pending results of
diagnostic testing for leptospirosis. If vomiting or other
adverse reactions preclude doxycycline administration,
dogs with leptospirosis should be treated with ampicillin,
20mg/kg IV q6h, with dose reduction for azotemic dogs.
Penicillin G (25,000–40,000U/kg IV q12h) also could be
used. Ampicillin should not be administered orally be-
cause it is not reliably absorbed from the gastrointestinal
tract.
115 Dogs should receive doxycycline for 2 weeks after
gastrointestinal signs abate in order to eliminate organ-
isms from the renal tubules. Concurrent ﬂuoroquinolone
useis not recommendedin dogswithleptospirosisbecause
it contributes to antimicrobial resistance in other bacteria.
Additional prospective studies that evaluate clearance of
organisms from the blood and urine with different antimi-
crobials are indicated in dogs.
When Should Dialysis Be Recommended for
Treatment of Canine Leptospirosis?
Renal replacement therapy with intermittent hemodi-
alysis or continuous renal replacement therapy (CRRT)
can be life-saving for many dogs with severe anuric
leptospirosis.
16,a More than 80% of patients that would
otherwise die from the consequences of severe uremia
survive with supportive renal replacement therapy.
Recovery of adequate renal function usually occurs
within 2–4 weeks of starting dialysis. Sometimes only
1–3 treatments are required before polyuria ensues and
renal function begins to recover. Early hemodialysis has
been associated with increased survival and shorter hos-
pital stays in human patients with leptospirosis.
116 Renal
replacement therapy is indicated in dogs with inadequate
urine output that are developing volume overload,
hyperkalemia, BUN 4 80mg/dL, or signs of uremia that
are not responsive to medical management. Increased
availability of hemodialysis will help more dogs survive
this disease. Practitioners should consider early referral
of dogs failing to produce adequate urine volume despite
proper ﬂuid therapy to centers with intermittent hemodi-
alysis or CRRT facilities when client ﬁnances allow.
How Should LPHS in Dogs Be Treated?
Dogs with LPHS may require oxygen therapy and, if
severe, mechanical ventilation. Studies of human patients
with LPHS showed improved outcome after cyclophosph-
amide therapy and plasma exchange.
25,117 Whether dogs
with LPHS would also beneﬁt from cyclophosphamide
treatment remains to be determined. Treatment of humans
and dogs with respiratory complications with dexametha-
sone and desmopressin has not improved outcome.
118,g
What is the Expected Response to Therapy?
Provided severe respiratory complications are absent,
the prognosis for dogs treated early and aggressively in
the course of leptospirosis with appropriate antimicrobi-
al drugs and IV ﬂuids, with or without diuretics, is good,
especially when intermittent hemodialysis is available.
Survival rates of approximately 80% have been reported,
both among dogs treated conservatively and those
treated with dialysis,
13,16 although virtually all dogs that
are dialysis dependent and do not receive dialysis would
be expected to die. The prognosis for dogs developing se-
vere respiratory complications is poorer.
20,b,f A high
prevalence of respiratory complications contributed to
overall mortality rates of 48 and 36% in 2 studies from
western Europe, respectively.
20,b
Successful treatment is associated with gradual return
of serum urea and creatinine concentrations to reference
ranges within 10–14 days, although regeneration of dam-
aged renal tissue may continue for over 4 weeks after
treatment of infection. The bilirubin concentration may
decline more slowly than the activities of serum ALT and
ALP. Platelet counts often improve within 1 week of ini-
tiating antimicrobial treatment. In some dogs, especially
those treated late in the course of illness, permanent re-
sidual kidney damage may occur. IV ﬂuid therapy should
be tapered gradually before being discontinued, to ensure
that polyuria is resolving and the patient is able to drink
sufﬁcient water to maintain hydration. Prolonged
inappetence may require nutritional support by enteral
or parenteral routes.
What Clinicopathologic Variables Should
Be Monitored during Treatment for
Canine Leptospirosis?
Dogs with acute leptospirosis ideally should have serum
biochemistry panels performed every 24 hours during hos-
pitalization to monitor renal function, liver enzyme
activities, serum protein concentrations, and electrolyte
and acid-base status. More frequent monitoring may be
indicated for dogs with marked electrolyte and acid-base
derangements. PCV should be monitored every 24 hours,
and the CBC every 48 hours during hospitalization.
Dogs with nonoliguric renal failure may be profoundly
polyuric. Fluid therapy may be provided by the ‘‘outs and
7 Leptospirosisins’’ method. Some patients may require ﬂuid rates
4200mL/kg/d. For dogs with oliguric or anuric renal fail-
ure, close attention should be paid to urine output by use
of a closed, indwelling urinary catheter and collection bag
system. Initially, urine output should be monitored at least
hourly. Referral to a 24-hour care facility is recommended
if adequate time for monitoring is not available in the
practice. Indwelling, rather than intermittent, urinary cath-
eterization is recommended for dogs requiring urinary
catheterization because of decreased risk of exposure to in-
fected urine with indwelling catheterization. Serial physical
examinations with frequent monitoring of body weight,
respiratory rate, lung sounds, blood pressure, and, if pos-
sible, central venous pressure are indicated to assess for
early signs of overhydration that might necessitate diuretic
therapy or dialysis. Once a patient is appropriately hy-
drated, ﬂuid administration must be adjusted to prevent
life-threatening ﬂuid overload.
Although follow-up will vary from dog to dog, at a
minimum, dogs should be reexamined no later than 1
week after discharge from the hospital, and a serum bio-
chemistry panel and urine speciﬁc gravity should be
performed. If thrombocytopenia or anemia were present
during hospitalization, a CBC could also be performed.
This also represents an opportunity to obtain convales-
cent antibody titers.
What Are the Public Health Implications of
Canine Leptospirosis?
Leptospirosis in humans occurs after an incubation
period of 2–25 days, and varies in severity.
1,4,95 Infection
in some humans is subclinical. Others develop a mild,
inﬂuenza-like illness. The most severe manifestations of
leptospirosis in humans are hepaticandrenalfailure (Weil’s
disease) or LPHS. Weil’s disease typically occurs 1 week
after recovery from an initial febrile illness that is accom-
panied by myalgia, headache, chills, and conjunctivitis.
1
The public health implications of canine leptospirosis
vary geographically. In developing countries, stray dogs
may represent a reservoir of infection for humans,
67 al-
though rodents also may play a role.
69,119 In developed
countries, most leptospirosis cases in humans result from
recreational activities involving water.
53,55,120 Individu-
als that contact farm animals are also at risk.
52,121 In 1
study, 10% of 61 leptospirosis cases in humans in Cali-
fornia over the last 20 years resulted from pet contact.
122
Contact with adopted wild rodents also has resulted in
human disease.
123,124
In general, animals developing acute leptospirosis are
incidental hosts and do not develop a chronic carrier
state. Transmission from incidental hosts to other ani-
mals is rarely reported,
4 and the few reports
72,125–127
suggesting transmission of leptospirosis from pet dogs
to humans have not been substantiated by molecular
methods. The extent of shedding of speciﬁc leptospiral
serovars by dogs after infection requires evaluation. An-
ecdotal evidence suggests it is difﬁcult to detect
leptospires in the urine of dogs receiving penicillin or
doxycycline treatment, and thus appropriate antimicro-
bial therapy may also decrease the possibility of zoonotic
transmission. Nevertheless, the full impact of antimicro-
bial therapy on leptospiral shedding from infected dogs
requires further study. Positive PCR results detected in
animals receiving antimicrobial therapy may reﬂect non-
viable organisms, which would not be a zoonotic risk.
What Recommendations Should Be Made to
Minimize the Risk of Zoonotic Transmission
in the Hospital?
Having a high index of suspicion for leptospirosis in
dogs with renal injury and handling them appropriately
may decrease zoonotic transmission of leptospires in the
hospital. All dogs with acute renal failure, including
‘‘acute-on-chronic’’ renal failure, should be managed as
leptospirosis suspects until an alternate diagnosis has
been made. Based on rodent model studies, viable organ-
isms are most likely to be present in blood or urine before
initiating antimicrobial therapy, and within the ﬁrst 2–3
days of treatment.
113 Leptospires might be shed for
months in urine if appropriate antimicrobial treatment
is not initiated. Leptospires generally survive poorly in
the environment and are susceptible to UV irradiation,
dessication, and routine disinfectants, although the de-
gree to which organisms could survive in urine-soaked
hair is unknown. Caution is recommended when han-
dling dogs suspected to have leptospirosis. The
movement of dogs suspected to have leptospirosis
around the hospital should be minimized, and areas of
contact should be disinfected. Warning labels should be
placed on cages of dogs suspected to have leptospirosis,
and pregnant or immunocompromised humans should
avoid contact with these patients. Because many of these
dogs are critically ill and require frequent monitoring,
and leptospires are not readily transmitted between dogs,
housing in isolation is not necessary. If possible, patients
should be placed in ﬂoor-level cages and housed away
from high trafﬁc areas. Care should be taken to avoid
needle-stick injuries and other blood contact. Gloves and
a disposable gown should be worn, and either protective
eyewear and a facemask, or, alternatively, a full face
shield should be worn if aerosolization of urine is possi-
ble, such as when manipulating urinary catheters or
collection systems, or when cleaning areas of urine spill-
age.
128 Pressure washing of runs should be avoided as it
may contribute to urine aerosolization. An indwelling
urinary catheter should be placed if urine output requires
monitoring, or if urinary incontinence is present, to min-
imize urinary contamination of the environment. If a
urinary catheter is not in place, dogs should be walked
frequently enough that urination does not occur in the
hospital, and preferably by a route that avoids common
hallways. Patients also could be moved through the hos-
pital on a gurney. They should be allowed to urinate in
a restricted area, preferably one that can be easily and
immediately decontaminated, such as on a hard, nonper-
meable surface that is free of organic matter. If urine
spills occur, they should be disinfected and cleaned
immediately. Bathing of hair that becomes soaked in
urine is recommended. Hand washing should be per-
formed before and after handling each patient after glove
8 Sykes et alremoval, and cages should be thoroughly cleaned and
disinfected daily. Gloves, a disposable gown, and face
protection should be worn when handling soiled bedding
and when cleaning cages or runs. Normal laundering of
soiled bedding will inactivate leptospires, but individuals
handling the bedding should wear protective clothing.
Disposable bedding should be placed in biohazard bags
and handled appropriately.
Urine collected from dogs with leptospirosis can be in-
activated with disinfectant solutions (eg, 1:1 aqueous
dilution of 10% bleach solution) and should be disposed
of properly. Iodine-based disinfectants, accelerated hy-
drogen peroxide, and quaternary ammonium solutions
also are effective. In dogs with indwelling urinary cathe-
ters, disinfectant should be injected directly into the
collection bag before disposing of the urine. In desig-
nated outdoor areas where infected dogs have urinated,
treatment of the area with 10% bleach solution is recom-
mended. All blood, urine, and tissues from dogs
suspected to have leptospirosis should be treated as med-
ical waste, and the handling of such material may vary
depending on local regulations.
129 If a dog dies or is eu-
thanized, individuals handling the remains should be
alerted of the zoonotic potential of the carcass.
All personnel that may have had direct or indirect con-
tact with a dog suspected to have leptospirosis should be
informed of the risks. These people include radiology
personnel and laboratory personnel handling blood,
urine, or tissue samples from patients.
Veterinarians should contact their local or state health
department or the Centers for Disease Control and
Prevention for guidance if additional questions arise re-
garding the public health risks and zoonotic transmission
of leptospirosis.
Should Dogs Living with Dogs Diagnosed with
Leptospirosis Be Treated?
Subclinical seroconversion has been documented in some
dogs living in the same household with dogs with leptospiro-
sis, possibly as a result of common exposure. Because of the
zoonotic potential of leptospirosis, treatment of other dogs
in the household that may have been coincidentally exposed
to a source of leptospires in the environment is recom-
mended, ideally with monitoring of acute and convalescent
phase antibody titers. The recommended treatment is doxy-
cycline, 5mg/kg PO q12h for 14 days.
What Recommendations Should Be Made to
Minimize the Risk of Zoonotic Transmission
within the Home?
Treated dogs represent a low risk to household mem-
bers. In addition, urinary shedding usually does not
commence until 7–10 days after infection, and conse-
quently dogs in the ﬁrst few days of illness also may not
represent a clinically relevant source of infection. Never-
theless, until proper antimicrobial therapy is completed,
owners should avoid contact with their dog’s urine and
wear gloves when cleaning up urine. Routine household
disinfectants should be used to clean areas of urine con-
tamination in the home. Dogs should be taken to urinate
and should urinate away from standing water, where no
other animals and people, especially children, will have
access. Owners should be advised to wash their hands af-
ter handling their pets. Upon diagnosis of leptospirosis,
veterinarians should educate owners of the zoonotic po-
tential of leptospirosis, and recommend they seek
medical attention if illness occurs around the time their
dog is diagnosed with leptospirosis or if they have ques-
tions about the disease in humans. Internet resources
128
also can be provided. Immunocompromised humans
should be referred to their medical practitioner for ad-
vice. Routine vaccination of dogs at risk of developing
leptospirosis may decrease the risk of zoonotic transmis-
sion of the disease. Owners should be informed that their
dog likely contracted leptospirosis by direct or indirect
contact with wild or farm animals, which may represent
ongoing risk factors.
What Vaccines Currently Are Available for
Canine Leptospirosis?
Currently, vaccines containing serovars Icterohaemor-
rhagiae, Canicola, Grippotyphosa, and Pomona are
available in North America for prevention of canine
leptospirosis. At the time of writing, bivalent vaccines
containing Icterohaemorrhagiae and Canicola are avail-
able in other geographic locations including North
America, Europe, South Africa, and Australia.
How Effective Are Vaccines Against Canine
Leptospirosis? Do They Prevent Development
of the Carrier State? What Is the Duration of
Immunity after Vaccination?
Current vaccines appear to effectively prevent disease
resulting from experimental challenge and to a large de-
gree prevent shedding caused by the serovars in the
vaccine. They also protect for at least 12 months.
21,78,h
Currently available bacterins elicit serogroup-speciﬁc im-
munity, but partial immunity to heterologous serogroups
has been documented in some studies.
80,130–132 Naturally
occurring canine leptospirosis has been reported after
vaccination with bivalent serovar Icterohaemorrhagiae
and Canicola vaccines.
20 The panel is unaware of
leptospirosis in dogs that have been fully vaccinated with
4-serovar vaccines, but published data are lacking regard-
ing the incidence of naturally occurring leptospirosis in
such dogs. This may partly relate to the difﬁculty in deﬁn-
itively diagnosing leptospirosis in fully vaccinated dogs.
What Adverse Effects Might Be Associated with
Vaccination for Canine Leptospirosis?
Concern has been raised regarding the development of
anaphylactoid reactions in dogs after leptospirosis vacci-
nation, especially small breed dogs, although such
reactions may occur in any breed. There is anecdotal evi-
dence from veterinarians and industry that the prevalence
of these reactions is decreasing, and may be similar to the
rate induced by vaccines for other pathogens. In a study of
9 Leptospirosisacute vaccine reactions in dogs utilizing a large database,
vaccines containing leptospiral antigen were no more reac-
tive than other vaccines for dogs.
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When Should Vaccination Be Recommended for
Prevention of Canine Leptospirosis?
Annual vaccination with 4-serovar vaccines is recom-
mended for at-risk dogs, regardless of breed, with the
understanding that the deﬁnition of ‘‘at-risk’’ may vary
geographically. In geographic locations in which infection
occurs in urban, backyard dogs, all dogs may be at risk,
and the vaccine may be considered part of a core vaccina-
tion protocol. In other locations, only dogs that contact
wildlife, swim, hunt, or roam on farmland may be at risk.
What Other Preventative Measures Can Be
Recommended to Prevent Canine Leptospirosis?
Other methods of prevention include decreased access
to potential sources of infection, such as marshy areas
and standing water, and minimizing wild animal contact
by use of fencing and rodent control.
CanDogsThatHaveRecoveredfromLeptospirosis
Be Reinfected?
Evidence of recurrent leptospirosis in dogs after
proper treatment is lacking. Nevertheless, annual vacci-
nation for dogs that have recovered from leptospirosis
could be considered, because such dogs are at risk of on-
going exposure, and whether or not life-long immunity
results from natural infection is unknown. The duration
of immunity in dogs after natural infection is likely to be
at least as long as that induced by vaccination, and thus
initial vaccination after recovery should occur 1 year
after recovery. Although natural infection may elicit
only partial cross-protective immunity to heterologous
serogroups, dogs are most likely to be reexposed to a
similar serovar to that involved in the initial infection.
There is little evidence supporting the need for immediate
boostering with a multivalent vaccine after recovery
from infection. More studies are required to establish
the true duration of immunity and degree of cross-
protection among speciﬁc serovars after natural infec-
tion in dogs.
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